ReviewExpert opinion on drug delivery2009
Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.
Review in Expert opinion on drug delivery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.
- Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- Optimization of lymphatic drug delivery system with carboplatin for metastatic lymph nodes.Scientific reports · 2025Article
- Emerging strategies in lymph node-targeted nano-delivery systems for tumor immunotherapy.Essays in biochemistry · 2025Review
- Decreased lymph node estrogen levels cause nonremitting progressive experimental autoimmune encephalomyelitis disease.PNAS nexus · 2025Article
- Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring.Nano convergence · 2024Review
- Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.Clinical and translational science · 2024Article
- Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes.Pharmacological reviews · 2024Review
- Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers.Asian journal of pharmaceutical sciences · 2024Review
- Entry and exit of extracellular vesicles to and from the blood circulation.Nature nanotechnology · 2024Review
- Therapeutic ultrasound: an innovative approach for targeting neurological disorders affecting the basal ganglia.Frontiers in neuroanatomy · 2024Review
- DFT study of therapeutic potential of graphitic carbon nitride as a carrier for controlled release of melphalan: an anticancer drug.Journal of molecular modeling · 2022Article
- Drug Release from Gelsolin-Targeted Phase-Transition Nanoparticles Triggered by Low-Intensity Focused Ultrasound.International journal of nanomedicine · 2022Article
- Near-infrared upconversion multimodal nanoparticles for targeted radionuclide therapy of breast cancer lymphatic metastases.Frontiers in immunology · 2022Article
- Preparation of the Biodegradable Lymphatic Targeting Imaging Agent Based on the Indocyanine Green Mesoporous Silicon System.Frontiers in chemistry · 2022Article
- VEGFR3 tyrosine kinase inhibition aggravates cisplatin nephrotoxicity.American journal of physiology. Renal physiology · 2021Article
- Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke.International journal of molecular sciences · 2021Review
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.Pharmaceutics · 2021Review
- Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.Cellular and molecular life sciences : CMLS · 2021Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer is the second leading cause of death in the US. Currently, protocols for cancer treatment include surgery to remove diseased and suspect tissues, focused radiation, systemic chemotherapy, immunotherapy and their combinations. With conventional chemotherapy, it is almost impossible to deliver anticancer drugs specifically to the tumor cells without damaging healthy organs or tissues. Over the past several decades, efforts have been made to improve drug delivery technologies that target anticancer drugs specifically to tumor cells. It has been known for over four decades that the lymphatics are the first site of metastasis for most solid cancers; however, few efforts have been made to localize chemotherapies to lymphatic tissues. Trials of several systemic targeted drug delivery systems based on nanoparticles containing chemotherapeutic agents (e.g., liposomal doxorubicin) have shown similar antitumor activity but better patient tolerance compared with conventional formulations. Animal studies have demonstrated that nanoparticles made of natural or synthetic polymers and liposomal carriers have higher accumulation in the lymph nodes and surrounding lymphatics compared to conventional intravenous therapies. This combination has the potential to both reduce nonspecific organ toxicities and increase the chemotherapeutic dose to the most likely sites of locoregional cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.